Effects of Moracizine Combined with Metoprolol on Hemodynamic Indices of the Left Atrium and Quality of Life in Patients with Atrial Fibrillation
DOI:
https://doi.org/10.59958/hsf.5683Keywords:
moracizine, metoprolol, atrial fibrillation, hemodynamic indices, quality of lifeAbstract
Background: Drugs are the first choice of treatment for atrial fibrillation (AF), but there is currently a lack of efficient drug treatment options. The aim of this study was to investigate a combination drug treatment plan which may serve as a reference for the treatment of AF. Methods: A total of 316 AF patients admitted to Jiaozhou Central Hospital in Qingdao from October 2020 to October 2022 were selected for this retrospective study. They were divided into a control group (CG, metoprolol, n = 156) and an observation group (OG, moracizine combined with metoprolol, n = 160) based on the treatment they received. The CG and OG groups were compared for clinical efficacy, occurrence of AF, cardiac output (CO), cardiac indexes (CI), stroke volume (SV), stroke indexes (SI) and improvement in QOL. Results: The OG had a better effective rate of treatment, higher levels of CO, CI, SV and SI, and higher QOL scores compared to the CG, as well as a lower AF recurrence rate and AF burden (all p < 0.05). Conclusion: Moracizine combined with metoprolol is an effective treatment for AF patients. This drug combination was found to reduce the AF recurrence rate and burden in AF patients, and to improve their hemodynamic indices and QOL.
References
Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, Weert HCPMV. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiologica. 2022; 77: 191–195.
Aldana-Bitar J, Moore J, Manubolu VS, Dahal S, Verghese D, Lakshmanan S, et al. Plaque Progression Differences Between Apixaban and Rivaroxaban in Patients With Atrial Fibrillation Measured With Cardiac Computed Tomography and Plaque Quantification. American Journal of Therapeutics. 2023; 30: e313–e320.
Nielsen PB, Søgaard M, Jensen M, Ording AG, Lip GY. Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. International Journal of Stroke. 2022; 17: 536–544.
Benz AP, Healey JS, Chin A, Commerford P, Marsden T, Karthikeyan G, et al. Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular Research. 2022; 118: 295–304.
Zou T, Chen Q, Chen C, Liu G, Ling Y, Pang Y, et al. Moricizine prevents atrial fibrillation by late sodium current inhibition in atrial myocytes. Journal of Thoracic Disease. 2022; 14: 2187–2200.
Nuñez Cruz S, DeMott JM, Peksa GD, Slocum GW. Evaluation of the blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. The American Journal of Emergency Medicine. 2021; 46: 329–334.
McGrath P, Kersten B, Chilbert MR, Rusch C, Nadler M. Evaluation of metoprolol versus diltiazem for rate control of atrial fibrillation in the emergency department. The American Journal of Emergency Medicine. 2021; 46: 585–590.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191–2194.
Halperin LF, Lee MK, Liew J, Lauck S, Kong D, Krahn AD, et al. Anticoagulation for Patients With Atrial Fibrillation and End-Stage Renal Disease on Dialysis: A National Survey. The Canadian Journal of Cardiology. 2021; 37: 924–928.
Jin C, Cui C, Seplowe M, Lee KI, Vegunta R, Li B, et al. Anticoagulation for Atrial Fibrillation: A Review of Current Literature and Views. Cardiology in Review. 2022. (online ahead of print)
Zhao Y, Krupadev V, Dagher L, Mahnkopf C, Sohns C, Sehner S, et al. Pharmacological rhythm versus rate control in patients with atrial fibrillation and heart failure: the CASTLE-AF trial. Journal of Interventional Cardiac Electrophysiology. 2021; 61: 609–615.
Fanaroff AC, Li S, Marquis-Gravel G, Giri J, Lopes RD, Piccini JP, et al. Atrial Fibrillation and Coronary Artery Disease: A Long-Term Perspective on the Need for Combined Antithrombotic Therapy. Circulation. Cardiovascular Interventions. 2021; 14: e011232.
Eyuboglu M. Frontal plane QRS-T angle in the monitoring of intravenous amiodarone infusion for pharmacological cardioversion of acute atrial fibrillation. Journal of Clinical Pharmacy and Therapeutics. 2021; 46: 731–737.
Marum AA, Araujo Silva B, Bortolotto AL, Pedreira GC, Tessarolo Silva F, Medeiros SA, et al. Pulmonary Delivery of Metoprolol Reduces Ventricular Rate During Atrial Fibrillation and Accelerates Conversion to Sinus Rhythm. Journal of Cardiovascular Pharmacology. 2020; 75: 135–140.
Vinereanu D, Spinar J, Pathak A, Kozlowski D. Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review. American Journal of Therapeutics. 2020; 27: e183–e193.
Compagner CT, Wysocki CR, Reich EK, Zimmerman LH, Holzhausen JM. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. The American Journal of Emergency Medicine. 2022; 62: 49–54.
DiNicolantonio JJ, Beavers CJ, Menezes AR, Lavie CJ, O'Keefe JH, Meier P, et al. Meta-analysis comparing carvedilol versus metoprolol for the prevention of postoperative atrial fibrillation following coronary artery bypass grafting. The American Journal of Cardiology. 2014; 113: 565–569.
Hargrove KL, Robinson EE, Lusk KA, Hughes DW, Neff LA, Fowler AL. Comparison of sustained rate control in atrial fibrillation with rapid ventricular rate: Metoprolol vs. Diltiazem. The American Journal of Emergency Medicine. 2021; 40: 15–19.
Liu Y, Hong Y. Amiodarone vs. metoprolol succinate in HFrEF complicated with persistent atrial fibrillation with rapid ventricular response: A prospective observational study. Frontiers in Cardiovascular Medicine. 2023; 9: 1029012.
Niforatos JD, Ehmann MR, Balhara KS, Hinson JS, Ramcharran L, Lobner K, et al. Management of atrial flutter and atrial fibrillation with rapid ventricular response in patients with acute decompensated heart failure: A systematic review. Academic Emergency Medicine. 2023; 30: 124–132.
Jing Y, Xu J, Chen B, Xia D, Xia D, Tian Y, et al. Superior mesenteric artery embolism after radiofrequency ablation in regularly anticoagulated patients with paroxysmal atrial fibrillation: a case report. BMC Cardiovascular Disorders. 2023; 23: 56.
Chen J, Zhao Y, Ma C, Du X, He Y, Li H. Left atrial deformation and risk of transient ischemic attack and stroke in patients with paroxysmal atrial fibrillation. Medicine. 2023; 102: e32745.
Boivin-Proulx LA, Potter BJ, Dorais M, Perreault S. Evolution of and Evidence-Practice Gaps in Antithrombotic Management of Atrial Fibrillation Patients After Percutaneous Coronary Intervention. CJC Open. 2022; 5: 15–23.
Ken-Opurum J, Srinivas SS, Park S, Charland S, Revel A, Preblick R. Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillation. Journal of Comparative Effectiveness Research. 2023; 12: e230065.
Colunga Biancatelli RM, Congedo V, Calvosa L, Ciacciarelli M, Polidoro A, Iuliano L. Adverse reactions of Amiodarone. Journal of Geriatric Cardiology. 2019; 16: 552–566.
